Published in Cancer Weekly, December 17th, 2002
The technology is expected to enhance the efficiency of Millennium's drug discovery efforts.
Under the terms of the agreement, Millennium is licensed to practice Xenogen's real-time in vivo imaging technology and will purchase Xenogen's IVIS Imaging System and Living Image software package for oncology applications. Millennium also has options to purchase other elements of Xenogen's technology platform: ...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.